• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HDAC1 Gene Record

  • Summary
  • Interactions
  • Claims
  • HDAC1 3065 Druggable GenomeClinically Actionable

    Alternate Names:

    3065
    HISTONE DEACETYLASE 1
    HDAC1
    GON-10
    HD1
    RPD3
    RPD3L1
    601241
    4852
    ENSG00000116478
    OTTHUMG00000007529
    Q13547
    HDAC
    HDAC1_HUMAN
    PA29226
    T68547
    KDAC1

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:3.5.1.98
    Target Main Class Enzymes
    Target Subclass 3.5.1.98
    CancerCommons Reported Gene Name HDAC
    Gene Biotype PROTEIN_CODING
    (9 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Mimori S et al., 2013, 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor., Bioorg Med Chem Lett
    VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.
    Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
    Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
    Geng et al., 2006, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer., Cancer Res.
    Hirata Y et al., 2012, Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain., Bioorg Med Chem Lett
    Mai A et al., 2008, Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities., Bioorg Med Chem Lett
    Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
    Kiyokawa S et al., 2010, New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group., Bioorg Med Chem
    Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
    Hood K et al., 2016, Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma., J Adv Pract Oncol
    Xu et al., 2007, Histone deacetylase inhibitors: molecular mechanisms of action., Oncogene
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Guerrant W et al., 2013, Dual-acting histone deacetylase-topoisomerase I inhibitors., Bioorg Med Chem Lett
    Yang W et al., 2015, Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., Bioorg Med Chem
    Neelarapu R et al., 2011, Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes., J Med Chem
    Dallavalle S et al., 2009, Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors., Eur J Med Chem
    Olson DE et al., 2013, Discovery of the first histone deacetylase 6/8 dual inhibitors., J Med Chem
    Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
    Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
    Herman D et al., 2006, Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia., Nat Chem Biol
    Petrelli R et al., 2014, From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine., Bioorg Med Chem Lett
    Perrino E et al., 2008, New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity., Bioorg Med Chem Lett
    Thomas M et al., 2008, Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy., Bioorg Med Chem
    Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem
    Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
    Khan et al., 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors., Biochem. J.
    Olsen CA et al., 2009, Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides., J Med Chem
    Sodji QH et al., 2015, Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids., Eur J Med Chem
    Fass et al., 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin., ACS Med Chem Lett
    Benelkebir H et al., 2011, Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability., Bioorg Med Chem
    Bhansali P et al., 2011, Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation., J Med Chem
    Bhansali P et al., 2014, Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups., Eur J Med Chem
    Klausmeyer P et al., 2011, Histone deacetylase inhibitors from Burkholderia thailandensis., J Nat Prod
    Campbell CT et al., 2008, Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells., J Med Chem
    Baud MG et al., 2012, Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets., J Med Chem
    García J et al., 2011, Epigenetic profiling of the antitumor natural product psammaplin A and its analogues., Bioorg Med Chem
    Hong S et al., 2015, Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents., Eur J Med Chem
    Shi Y et al., 2007, Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition., Bioorg Med Chem Lett
    Chen IH et al., 2009, Cytotoxic triterpenoids from the stems of Microtropis japonica., J Nat Prod
    Schäfer S et al., 2008, Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs)., Bioorg Med Chem
    Charrier C et al., 2009, Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression., J Med Chem
    Marrazzo A et al., 2011, Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells., Eur J Med Chem
  • TUBASTATIN A   HDAC1

    Interaction Score: 2.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25899338


    Sources:
    DTC

  • CHEMBL152133   HDAC1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DEPUDECIN   HDAC1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHLAMYDOCIN   HDAC1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHEMBL152543   HDAC1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SPIRUCHOSTATIN C   HDAC1

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21967146


    Sources:
    DTC

  • MOCETINOSTAT   HDAC1

    Interaction Score: 0.81

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 1 inhibitor

    PMIDs:
    26287310 23829483 17455259 17868033


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TTD

  • ENTINOSTAT   HDAC1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name entinostat, SNDX-275, MS-275
    Notes

    PMIDs:
    22321215 18381238 19966789 20491440 20452226


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions TTD

  • BELINOSTAT   HDAC1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name PXD101
    Novel drug target Established target
    Notes

    PMIDs:
    25937017 28090369


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • PANOBINOSTAT   HDAC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Prostate
    Trial Name Panobinostat

    PMIDs:
    24694055 17455259 17145876


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial CancerCommons TTD

  • OBP-801   HDAC1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NANATINOSTAT   HDAC1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC TTD

  • TUCIDINOSTAT   HDAC1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • VORINOSTAT   HDAC1

    Interaction Score: 0.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase 1 inhibitor
    Direct Interaction yes
    Trial Name Merck

    PMIDs:
    17694093 11752352 23622981 19966789 26211462 21548582 20491440 24694055 19084294 23672185 22260166 19344175 18381238


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

  • TRICHOSTATIN   HDAC1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19966789 18054239 19385600 21055848 16921367 22280363


    Sources:
    DTC

  • ROMIDEPSIN   HDAC1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    21587264


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

  • DOMATINOSTAT   HDAC1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name 4SC-202

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • PSAMMAPLIN A   HDAC1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22280363 21215647 25884112


    Sources:
    DTC

  • TACEDINALINE   HDAC1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    18692397


    Sources:
    DTC ChemblInteractions

  • GIVINOSTAT   HDAC1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name ITF2357,Givinostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial TTD

  • DACINOSTAT   HDAC1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHIDAMIDE   HDAC1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Chidamide, HBI-8000
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • SCRIPTAID   HDAC1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19966789


    Sources:
    DTC TTD

  • VALPROIC ACID   HDAC1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16921367 25304896 18294844


    Sources:
    DTC

  • CUDC-101   HDAC1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name CUDC-101
    Mechanism of Interaction Histone deacetylase inhibitor

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial ChemblInteractions

  • PHENYLBUTANOIC ACID   HDAC1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24044874


    Sources:
    DTC TTD

  • CHEMBL117487   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17566732


    Sources:
    DTC

  • BUTANOIC ACID   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19053749


    Sources:
    DTC

  • CHEMBL1650245   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24044874


    Sources:
    DTC

  • BUTYRYLHYDROXAMIC ACID   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21874153


    Sources:
    DTC

  • CHEMBL324053   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16921367


    Sources:
    DTC

  • PHENYLBUTYRYLHYDROXAMIC ACID   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21874153


    Sources:
    DTC

  • APICIDIN   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19705846


    Sources:
    DTC

  • RESMINOSTAT   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Resminostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • SUBEROHYDROXAMIC ACID   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16921367


    Sources:
    DTC

  • ABEXINOSTAT   HDAC1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name PCI-27483, CRA-024781
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial

  • LARGAZOLE   HDAC1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21420302 21936551 25203782 20491440


    Sources:
    DTC

  • URSOLIC ACID   HDAC1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19534471


    Sources:
    DTC

  • DEPAKOTE   HDAC1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • AN-9   HDAC1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • PANOBINOSTAT LACTATE   HDAC1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AR-42   HDAC1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name AR-42
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • PRACINOSTAT   HDAC1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name SB939
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   HDAC1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23622981


    Sources:
    DTC

  • HINOKITIOL   HDAC1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FIMEPINOSTAT   HDAC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DAUNORUBICIN   HDAC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • Ensembl: ENSG00000116478

    • Version: 101_38

    Alternate Names:
    HDAC1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • CancerCommons: HDAC1

    • Version: 25-July-2013

    Alternate Names:
    3065 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name HDAC

    Publications:

  • TdgClinicalTrial: Q13547

    • Version: January-2014

    Alternate Names:
    HDAC1 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.5.1.98

    Publications:

  • TEND: Q13547

    • Version: 01-August-2011

    Alternate Names:
    3065 Entrez Gene Id
    ENSG00000116478 Ensembl Gene Id
    HDAC1 Gene Symbol

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 3.5.1.98

    Publications:

  • PharmGKB: HDAC1

    • Version: 18-August-2020

    Alternate Names:
    PA29226 PharmGKB ID

    Gene Info:

    Publications:
    Kim MH et al., 2013, A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics., Korean J Intern Med
    Ghodke-Puranik Y et al., 2013, Valproic acid pathway: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

  • DTC: HDAC1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
    Fass et al., 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin., ACS Med Chem Lett
    Kiyokawa S et al., 2010, New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group., Bioorg Med Chem

  • HingoraniCasas: ENSG00000116478

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000116478 Gene Symbol
    HDAC1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: HDAC1

    • Version: 20-Jun-2017

    Alternate Names:
    3065 Entrez Gene Id
    HDAC1 MyCancerGenome Gene Symbol
    HDAC MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • TALC: HDAC1

    • Version: 12-May-2016

    Alternate Names:
    HDAC1 Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: RPD3L1

    • Version: chembl_23

    Alternate Names:
    RPD3L1 GENE_SYMBOL
    HDAC1 GENE_SYMBOL
    Histone deacetylase 1 UNIPROT

    Gene Info:

    Publications:

  • Tempus: HDAC1

    • Version: 11-November-2018

    Alternate Names:
    HDAC1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Histone deacetylase 1

    • Version: 2020.06.01

    Alternate Names:
    HDAC1 TTD Gene Abbreviation
    T68547 TTD Target ID

    Gene Info:

    Publications:

  • FoundationOneGenes: HDAC1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21